AbbVie developed Telisotuzumab Vedotin (Teliso-V) an investigational antibody-drug conjugate (ADC), to treat patients with non-small cell lung cancer (NSCLC).
(Teliso-V) is used to treat patients with advanced/metastatic epidermal growth factor receptor (EGFR) wild type, nonsquamous non-small cell lung cancer (NSCLC) consisting of high levels of c-Met overexpression whose disease has advanced on or after platinum-based therapy.
Patients undergoing standard of care therapies, including prior platinum have limited treatment options and poor prognosis.
Currently there are no approved cancer therapies specifically for patients with c-Met overexpressing NSCLC. Teliso-V i in combination with osimertinib is being evaluated in the ongoing Phase 1 study M14-237 in patients with previously treated c-Met overexpressing NSCLC.
U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to investigational telisotuzumab vedotin (Teliso-V) for previously treated non-small cell lung cancer.
In U.S and worldwide, although having advanced treatments options lung cancer remains the most common type of cancer among both men and women. Moreover, it is the third most common cancer in females and affecting males. Approximately 85% of lung cancers are classified as NSCLC.
